Regeneron Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.63B | $1.54B | $1.63B | $1.48B | $1.42B | $1.33B | $1.41B | $1.27B |
| SG&A Expense | $662.1M | $647.7M | $775.0M | $657.8M | $634.2M | $633.0M | $792.2M | $714.4M |
| Operating Income | $1.29B | $642.9M | $879.9M | $1.03B | $1.08B | $591.7M | $990.2M | $1.18B |
| Operating Margin | 30.1% | 17.8% | 22.7% | 27.3% | 29.4% | 19.5% | 26.1% | 31.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $1.53B | $831.2M | $1.04B | $1.76B | $1.52B | $905.0M | $958.1M | $1.49B |
| Income Tax Expense | $230.9M | $104.0M | $199.1M | $303.3M | $127.1M | $96.3M | $40.4M | $152.4M |
| Net Income | $1.30B | $727.2M | $844.6M | $1.46B | $1.39B | $808.7M | $917.7M | $1.34B |
| Net Margin | 30.2% | 20.2% | 21.7% | 38.9% | 37.9% | 26.7% | 24.2% | 36.0% |
| EPS (Basic) | $12.62 | $6.99 | $8.16 | $14.09 | $13.24 | $7.58 | $8.55 | $12.40 |
| EPS (Diluted) | $12.23 | $6.75 | $7.78 | $13.62 | $12.81 | $7.27 | $8.12 | $11.54 |
| Shares Outstanding (Basic) | 102.8M | 104.0M | 104.6M | 103.6M | 105.1M | 106.7M | 107.9M | 108.1M |
| Shares Outstanding (Diluted) | 106.0M | 107.7M | 108.6M | 107.2M | 108.6M | 111.2M | 115.1M | 116.2M |
| Dividends Per Share | $0.94 | $0.94 | $0.88 | $0.88 | $0.88 | $0.88 | — | — |